Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

A radioactive, metal-based technology in the field of metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy, which can solve the problems of difficult RIT, unpredictable biological effects, prolonged circulation time, etc.

Pending Publication Date: 2020-06-16
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the use of radiolabeled antibodies for imaging, RIT is fraught with difficulties, including prolonged circulation times, unpredictable biological effects, and the occasional need for pre-targeting strategies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
  • Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
  • Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0312] Synthesis and Evaluation of Gadolinium (Gd)-Based Contrast Agents

[0313] overview

[0314] Magnetic resonance (MR) imaging is advantageous as it can simultaneously provide anatomical, functional and molecular information. MR molecular imaging can combine the ubiquity of this established clinical pattern and its high spatial resolution with in vivo molecular lineage profiling. However, due to the inherently low sensitivity of MR, high local concentrations of biological targets are required to generate discernible MR contrast. Due to the high concentration of prostate-specific membrane antigen (PSMA) in target cells, limited expression in non-target tissues, and accessibility on the cell surface, we hypothesized that prostate-specific membrane antigen (PSMA), for prostate cancer Attractive target for imaging and therapy, may serve as a suitable biomarker for MR-based molecular imaging. For this purpose, three high-affinity, low molecular weight gadolinium(Gd)(III...

Embodiment 2

[0347] Receptor concentration of PSMA

[0348] Number of receptors per cell (N.R.C.) = 4.9 x 10 6 one, r 细胞 =8.75μm

[0349]

[0350]

[0351] Therefore, in order to observe 0.05 seconds -1 change (approximately 10% enhancement, taking into account tissue T 0 1 = 2 seconds), requires relaxivity (if acceptor:contrast 1:1)

[0352]

Embodiment 3

[0354] 86 Preclinical Evaluation of a Y-Labeled Prostate-Specific Membrane Antigen Inhibitor for Dosimetry Estimation

[0355] overview

[0356] 86 Y (half-life=14.74h, 33%β + ) within an emerging class of positron-emitting isotopes with relatively long physical half-lives, enabling extended imaging of biological processes. Three low-molecular-weight 86 Preparation and biodistribution of Y-labeled PSMA-conjugated urea ( Figure 14 ), and the most pharmacokinetically favorable agent in non-human primates was used in the preparation of the corresponding 90 Y-and 177 Dosimetric Imaging of Lu-Labeled Reagents in Clinical Trials.

[0357] in preparation[ 86 Y]-4-6 used a multi-step synthesis. PSMA inhibition constants were assessed by competitive binding assays. In vivo characterization using tumor-bearing male mice up to 24h after injection by [ 86 Y]-4-6 PET / CT and passed [ 86 Y]-4 and [ 86Y]-6 biodistribution studies were performed. Record quantitative whole-bo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The present application relates to metal / radioactive metal labeled PSMA inhibitors for PSMA targeted imaging and radiotherapy. The invention relates to low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA- specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA- targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.

Description

[0001] This application is a divisional application of the application dated May 6, 2015, the application number is 201580036857.1, and the title of the invention is "Metal / radiometal-labeled PSMA inhibitor for PSMA-targeted imaging and radiotherapy". [0002] Cross References to Related Applications [0003] This application claims the benefit of U.S. Provisional Application No. 61 / 989,428, filed May 6, 2014, and U.S. Provisional Application No. 62 / 117,603, filed February 18, 2015, each of which is incorporated by reference in its entirety into this article. technical field [0004] This application relates to, but is not limited to, metal / radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiation therapy. Background technique [0005] Prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for other forms of imaging and therapy of prostate and cancer (Ghosh and Heston, 2004; Milowsky et al., 2007; Olson et al., 2007). PSMA ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/062C07D403/14A61K51/04A61K51/08A61K49/00A61K49/10A61K49/14A61P35/00A61K103/30A61K103/40A61K103/00A61K103/20A61K103/32
CPCA61K49/106A61K49/12A61K51/0482A61K51/06C07D403/14A61K49/0002A61K51/0497A61K51/0402C07D257/02A61P35/00A61K49/108
Inventor S·雷M·G·庞珀托马斯·J·米德罗尼·C·米斯陈颖杨星马修·罗茨
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap